Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Randomized Controlled Trial Assessing the Impact of Tacrolimus Versus Cyclosporine on the Incidence of Posttransplant Diabetes Mellitus

  • Torres, Armando|||0000-0003-1121-5173
  • Hernández, Domingo
  • Moreso, Francesc|||0000-0002-7267-3963
  • Seron, Daniel|||0000-0003-2054-653X
  • Burgos, María Dolores
  • Pallardó, Luis M.
  • Kanter, Julia
  • Díaz-Corte, Carmen
  • Rodríguez, Minerva
  • Díaz Gómez, Juan Manuel|||0000-0002-5653-6619
  • Silva, Irene|||0000-0002-2723-1031
  • Valdes, Francisco
  • Fernández-Rivera, Constantino
  • Osuna, Antonio
  • Gracia Guindo, María C.
  • Gómez Alamillo, Carlos
  • Ruiz, Juan C.
  • Marrero Miranda, Domingo
  • Pérez-Tamajón, Lourdes
  • Rodríguez, Aurelio
  • González-Rinne, Ana
  • Alvarez, Alejandra
  • Perez-Carreño, Estefanía
  • de la Vega Prieto, María José
  • Henriquez, Fernando
  • Gallego Samper, Roberto
  • Salido, Eduardo
  • Porrini, Esteban
Despite the high incidence of posttransplant diabetes mellitus (PTDM) among high-risk recipients, no studies have investigated its prevention by immunosuppression optimization. We conducted an open-label, multicenter, randomized trial testing whether a tacrolimus-based immunosuppression and rapid steroid withdrawal (SW) within 1 week (Tac-SW) or cyclosporine A (CsA) with steroid minimization (SM) (CsA-SM), decreased the incidence of PTDM compared with tacrolimus with SM (Tac-SM). All arms received basiliximab and mycophenolate mofetil. High risk was defined by age.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of HLA Mismatching on Early Subclinical Inflammation in Low-Immunological-Risk Kidney Transplant Recipients

  • Hernández, Domingo
  • Vázquez, Teresa
  • Alonso-Titos, Juana
  • León, Myriam
  • Caballero, Abelardo
  • Cobo, María Angeles
  • Sola, Eugenia|||0000-0002-9462-3342
  • López Jiménez, Verónica|||0000-0002-1793-7065
  • Ruiz-Esteban, Pedro
  • Cruzado, Josep María
  • Sellarés, Joana
  • Moreso, Francesc|||0000-0002-7267-3963
  • Manonelles, Anna|||0000-0003-2456-388X
  • Torio, Alberto
  • Cabello, Mercedes
  • Delgado-Burgos, Juan
  • Casas, Cristina
  • Gutiérrez, Elena
  • Jironda, Cristina
  • Kanter, Julia
  • Seron, Daniel|||0000-0003-2054-653X
  • Torres, Armando|||0000-0003-1121-5173
The impact of human leukocyte antigen (HLA)-mismatching on the early appearance of subclinical inflammation (SCI) in low-immunological-risk kidney transplant (KT) recipients is undetermined. We aimed to assess whether HLA-mismatching (A-B-C-DR-DQ) is a risk factor for early SCI. As part of a clinical trial (Clinicaltrials.gov, number NCT02284464), a total of 105 low-immunological-risk KT patients underwent a protocol biopsy on the third month post-KT. As a result, 54 presented SCI, showing a greater number of total HLA-mismatches (p = 0.008) and worse allograft function compared with the no inflammation group (48.5 ± 13.6 vs. 60 ± 23.4 mL/min; p = 0.003). Multiple logistic regression showed that the only risk factor associated with SCI was the total HLA-mismatch score (OR 1.32, 95%CI 1.06-1.64, p = 0.013) or class II HLA mismatching (OR 1.51; 95%CI 1.04-2.19, p = 0.032) after adjusting for confounder variables (recipient age, delayed graft function, transfusion prior KT, and tacrolimus levels). The ROC curve illustrated that the HLA mismatching of six antigens was the optimal value in terms of sensitivity and specificity for predicting the SCI. Finally, a significantly higher proportion of SCI was seen in patients with.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Treatment of early borderline lesions in low immunological risk kidney transplant patients, a Spanish multicenter, randomized, controlled parallel-group study protocol: the TRAINING study

  • Hernández, Domingo
  • Vázquez Sánchez, Teresa
  • Sola, Eugenia|||0000-0002-9462-3342
  • Lopez, Veronica
  • Ruiz-Esteban, Pedro
  • Caballero, Abelardo
  • Salido, Eduardo
  • León, Myriam
  • Rodriguez, Aurelio
  • Serra, Núria|||0000-0001-7926-2625
  • Rodríguez, Consuelo
  • Facundo, Carme|||0000-0003-1254-5553
  • Perello, Manel
  • Silva, Irene|||0000-0002-2723-1031
  • Marrero-Miranda, Domingo
  • Cidraque, Ignacio
  • Moreso, Francesc|||0000-0002-7267-3963
  • Guirado, Luis|||0000-0001-5119-3912
  • Seron, Daniel|||0000-0003-2054-653X
  • Torres, Armando|||0000-0003-1121-5173
Subclinical inflammation, including borderline lesions (BL), is very common (30-40%) after kidney transplantation (KT), even in low immunological risk patients, and can lead to interstitial fibrosis/tubular atrophy (IFTA) and worsening of renal function with graft loss. Few controlled studies have analyzed the therapeutic benefit of treating these BL on renal function and graft histology. Furthermore, these studies have only used bolus steroids, which may be insufficient to slow the progression of these lesions. Klotho, a transmembrane protein produced mainly in the kidney with antifibrotic properties, plays a crucial role in the senescence-inflammation binomial of kidney tissue. Systemic and local inflammation decrease renal tissue expression and soluble levels of α-klotho. It is therefore important to determine whether treatment of BL prevents a decrease in α-klotho levels, progression of IFTA, and loss of kidney function. The TRAINING study will randomize 80 patients with low immunological risk who will receive their first KT. The aim of the study is to determine whether the treatment of early BL (3rd month post-KT) with polyclonal rabbit antithymocyte globulin (Grafalon®) (6 mg/kg/day) prevents or decreases the progression of IFTA and the worsening of graft function compared to conventional therapy after two years post-KT, as well as to analyze whether treatment of BL with Grafalon® can modify the expression and levels of klotho, as well as the pro-inflammatory cytokines that regulate its expression. This phase IV investigator-driven, randomized, placebo-controlled clinical trial will examine the efficacy and safety of Grafalon® treatment in low-immunological-risk KT patients with early BL. : NCT04936282. Registered June 23, 2021, . Protocol Version 2 of 21 January 2022. Sponsor: Canary Isles Institute for Health Research Foundation, Canary Isles (FIISC). mgomez@fciisc.org.